secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0001842952-23-000015
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics reports positive Phase 2 OATH data for ONA-XR in endometrial cancer
--------------------------------------------------------------------------------

- Two confirmed partial responses among first 12 patients (9 evaluable) in Phase 2 trial of ONA-XR plus anastrozole for HR+ metastatic endometrial cancer.
- 4-month progression-free survival rate of 77% and overall response rate of 22%; no drug-related discontinuations observed.
- Compared to historical KEYNOTE-775 trial: ONA-XR+ANA showed higher 4-month PFS (77% vs 42% chemo, 67% Lenvima+Keytruda) and lower discontinuation (0% vs 8% and 33%).
- Drug well-tolerated with mainly Grade 1-2 adverse events; updated data expected in Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295223000015/0001842952-23-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295223000015/cntx-20230206.htm
  HTML page:      https://secwatch.observer/filing/0001842952-23-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer